Business Editors & Health/Medical Writers
ADVISORY...for TUESDAY (Aug. 21)
NOTE TO EDITORS: Multimedia Assets Available With This Story
Include Logos, Text News Releases, Video
Novartis announced it has received marketing approval from the U.S. Food and Drug Administration (FDA) for ZOMETA(R) (zoledronic acid for injection; zo MET uh), a new generation intravenous (IV) bisphosphonate for the treatment of hypercalcemia of malignancy (HCM).
HCM is the most common life-threatening metabolic complication associated with cancer. Video news release available here.
You can reach the story directly by going to http://www.newstream.com/cgi-bin/display_story.cgi?3756
This multimedia news story is for free and unrestricted use on your news information site (and for print or broadcast too). Visit http://www.newstream.com to download video, audio, text, graphics and photos.
If you have any questions about the story, or about Newstream.com, please write to us at email@example.com.
COPYRIGHT 2001 Business Wire
COPYRIGHT 2001 Gale Group